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A key challenge facing global mental health has been addressing the large ‘treatment gaps’ for
neuropsychiatric disorders, to which large ‘detection gaps’ contribute significantly. The majority
of these conditions are diagnosed either very late, or not at all.1 Low- and middle-income
countries (LMICs) in particular present three barriers: low help-seeking behavior, in part due to
limited awareness and stigma associated with mental disorders; paucity of mental health
professionals to conduct diagnostic assessments; and reliance on diagnostic interviews many of
which are time-intensive or proprietary and may not be cross-culturally valid. 2 Identifying
biomarkers that could aid early detection of mental disorders is a major goal for neuroscience
research. Biomarkers may be defined as “any characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention”.3 Identification and characterization of biomarkers offers
a tantalizing new translational opportunity to address detection gaps in LMICs by enabling point-
of-care detection by non-specialist health workers. We illustrate our proposal through the
example of Autism Spectrum Disorders (ASD).
The priority placed on early detection of ASD has been recognized by high-income countries'
(HICs) development of large consortia that integrate multidisciplinary expertise for biomarker
discovery, such as the EU-AIMS (www.eu-aims.eu) and the ABC-CT (www.asdbiomarkers.org).
A variety of biomarkers, including genetic variations, proteomic and metabolic profiles, brain
anatomy and function, and markers of cognitive and behavioral deficits offer promise in
discriminating typically developing children from those with ASD.4 For LMICs to benefit from
such research, however, biomarker screening and detection methods must be low-cost, scalable,
acceptable to the end user and feasible for use in community settings and for delivery by non-
specialist frontline workers. Additionally, selected biomarkers must be highly sensitive and
specific, being able to identify children with ASD during community-level screening, while
limiting the number of false positives to avoid straining the limited health resources in LMICs
and minimizing adverse social consequences to those who do not have this condition. Such
‘point-of-care’ detection tools would pave the way for targeted referral to specialists for
confirmatory diagnostic assessments and early intervention programs.
Among direct child assessment measures, atypical eye gaze is one of the most promising
biomarkers of ASD.5 Various measures of neural connectivity and specific neural functions are
also associated with ASD.6 Bearing scalability in mind, portable eye-tracking technology and
electroencephalography currently have the most promise for ASD screening. These technologies
are non-invasive, applicable from infancy to adulthood and can be acquired on commercially
available, portable platforms. While near infrared spectroscopy shares some of these advantages,
there is currently limited evidence available to inform on its potential for use in detection of
ASD. LMICs can assess the potential of these promising biomarkers when evaluated on rapidly
evolving portable hardware, in less controlled recording environments, administered by non-
specialist community workers.
Although complex interactions between genetic vulnerability and environmental factors have
long been viewed as being causal to ASD, apart from a few single-gene disorders, no common
set of loci can reliably predict ASD.4 The identification of biomarkers in peripheral blood, such
as altered serotonin and glutamate and GABA levels, 7 could be particularly useful because the
logistics of cold-chain transport of biomaterials to analytical laboratories have been established
in most countries. Currently, the requirement of state-of-the-art, expensive, laboratory-based
genomic and proteomic technologies to assess these biomarkers poses a limitation in LMICs;
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however, as with polymerase chain reaction technologies for the diagnosis of infectious diseases,
there is a potential for investment in their adaptation for scalability if diagnostic properties prove
to be robust. 
Mobile health (mHealth) platforms have immense potential to address the multiple challenges
illustrated above.8 In the context of ASD, while there are a number of tablet-based interventions
readily available,9 there are relatively few tablet-based detection tools. For instance, screening
questionnaires such as the Modified Checklist for Autism in Toddlers and the Social
Communication Disorder Checklist, which are now being used routinely in some HICs, can
readily be adapted onto mobile platforms from traditional paper-pencil methods, containing
programmed algorithms for scoring. A first step to such mHealth adaptations is to ensure
availability of culturally validated tools for screening and diagnosis in local languages. These
could be supplemented by videos demonstrating typical and ASD behavioural biomarkers to
assist parents in diverse cultural contexts to respond accurately to questions (http://asdetect.org/) .
Mobile applications containing automatic coding and analysis of video recordings of a child’s
facial expressions are also being currently tested.10 Eye-tracking assessments could also be fully
integrated within such mHealth platforms.
While ASD cannot yet be definitively differentiated from typical development in an individual
on the basis of any single biomarker, mHealth platforms offer the potential of combining and
triangulating information from assessment of multiple biomarkers. Bayesian statistical models
can be used to estimate the probability of ‘caseness’ based on findings drawn from a combination
of assessment methods to improve the accuracy of ASD risk prediction (Figure 1). In addition,
the integration of big data analytics and machine learning algorithms during development of such
a screening platform will allow refinement of screening algorithms through feedback of data on
the actual diagnosis of the individual. Such data from large-scale population-based surveillance
using an integrated mHealth platform may ultimately provide the evidence base for development
of a point-of-care diagnostic tool for ASD.
Despite a growing body of evidence on ASD biomarkers, and similar research in other mental
disorders, data on their application at the community level or in LMICs are limited. In parallel,
technologies need to evolve to fulfil the criteria of scalability and demonstrate potential for use
in natural, uncontrolled settings. Such advances also would benefit low-resource settings within
HICs. Further, the expansion of research initiatives to LMIC populations would allow evaluation
of biomarkers at global scales, incorporating diverse genetic and socio-cultural milieu. This is an
opportune time for neuroscientists, clinicians, public health researchers and engineers to
establish collaborative networks to design innovative solutions for detection of mental disorders
and to usher in a new era for global mental health.11 
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Figure Legend
Figure 1: Development of point-of-care ASD detection/diagnostic tool
a) Promising biomarkers, assessed using scalable technologies, can be integrated onto a
mobile screening platform. Probabilistic modelling can identify thresholds for each
biomarker individually and in combination to detect ASD.
b) Using scalable technologies, validation of the ‘biomarker package’ in large-scale
population studies will allow machine learning algorithms to refine biomarker thresholds
for a point-of-care diagnostic/detection tool for ASD.
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